Definium Therapeutics, Inc. (DFTX)
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical company reported positive topline results from its Phase 3 Emerge study evaluating DT120, an orally disintegrating formulation of lysergide (LSD), in adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled trial met its primary endpoint and all key secondary efficacy endpoints.
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
Definium Therapeutics NASDAQ: DFTX Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data in major depressive disorder later this quarter and ongoing Phase III work in generalized anxiety disorder.
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day Transcript
Definium Therapeutics, Inc. (DFTX) Analyst/Investor Day Transcript
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones
Definium Therapeutics, Inc. is maintained at a Strong Buy due to imminent 2026 catalysts and robust late-stage pipeline progress. DFTX expects three pivotal data readouts in 2026 from phase 3 trials of DT120 ODT for GAD and MDD, plus phase 2a data for DT402 in ASD. DT402 targets a large unmet need in adult ASD, leveraging a differentiated R(-)-MDMA profile with prior phase 1 safety validation.
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX
Ally Bridge Group NY LLC trimmed its holdings in shares of Definium Therapeutics, Inc. (NASDAQ: DFTX) by 50.2% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 361,444 shares of the company's stock after selling 364,728 shares during the period. Definium Therapeutics makes up approximately 2.6%
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
